245. プロピオン酸血症 Disease details / Clinical trials / Drug dev / DR info


臨床試験数 : 13 / 薬物数 : 16 - (DrugBank : 3) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 6

薬物ごとの開発者(Primary Sponsor)、臨床試験情報(抜粋)です。
BBP-671   
   CoA Therapeutics, Inc., a BridgeBio company
      2021   Phase 1   NCT04836494   United States;
CX-016492   
   ModernaTX, Inc
      2020   Phase 1;Phase 2   EUCTR2019-003529-36-GB   Canada;United Kingdom;United States;
CX-017950   
   ModernaTX, Inc
      2020   Phase 1;Phase 2   EUCTR2019-003529-36-GB   Canada;United Kingdom;United States;
Carbaglu   
   Mendel Tuchman
      2012   Phase 2   NCT01599286   United States;
Carglumic Acid (Carbaglu®)   
   National Taiwan University Hospital
      2019   -   NCT04284917   Taiwan;
Disodium citrate   
   Nicola Longo
      2008   Phase 1   NCT00645879   United States;
Glutamine   
   Nicola Longo
      2008   Phase 1   NCT00645879   United States;
HST5040   
   HemoShear Therapeutics
      2021   Phase 2   NCT04732429   United States;
MRNA-3927   
   ModernaTX, Inc
      2020   Phase 1;Phase 2   EUCTR2019-003529-36-GB   Canada;United Kingdom;United States;
   ModernaTX, Inc.
      2021   Phase 1/Phase 2   NCT05130437   Canada;United Kingdom;United States;
      2021   Phase 1/Phase 2   NCT04159103   Canada;United Kingdom;United States;
Ornithine alpha ketoglutarate   
   Nicola Longo
      2008   Phase 1   NCT00645879   United States;